tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

GMAB Stock Latest News

Genmab price target lowered to DKK 1,500 from DKK 1,700 at JPMorgan
The FlyGenmab price target lowered to DKK 1,500 from DKK 1,700 at JPMorgan
15h ago
GMAB
Genmab reports ‘encouraging anti-tumor activity’ for Rina-S in Phase 1/2 trial
PremiumThe Fly
Genmab reports ‘encouraging anti-tumor activity’ for Rina-S in Phase 1/2 trial
5d ago
GMAB
Genmab Continues Share Buy-back Program Amid Strategic Financial Management
PremiumCompany Announcements
Genmab Continues Share Buy-back Program Amid Strategic Financial Management
5d ago
6K
GMAB
Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital
PremiumThe Fly
Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital
9d ago
GMAB
Genmab Executes Share Buy-back Transactions in May 2025
PremiumCompany Announcements
Genmab Executes Share Buy-back Transactions in May 2025
11d ago
6K
GMAB
Genmab’s Promising Rina-S Developments Drive Buy Rating Amid Strong Initial Study Results
PremiumRatingsGenmab’s Promising Rina-S Developments Drive Buy Rating Amid Strong Initial Study Results
11d ago
GMAB
Genmab’s Rina-S: Promising Efficacy and Strategic Growth Potential in Endometrial Cancer Treatment
Premium
Ratings
Genmab’s Rina-S: Promising Efficacy and Strategic Growth Potential in Endometrial Cancer Treatment
15d ago
GMAB
Genmab A/S Updates Articles to Enhance Capital Flexibility
Premium
Company Announcements
Genmab A/S Updates Articles to Enhance Capital Flexibility
17d ago
6K
GMAB
Genmab Announces Capital Increase Following Employee Warrant Exercise
PremiumCompany Announcements
Genmab Announces Capital Increase Following Employee Warrant Exercise
18d ago
6K
GMAB
Bolt Biotherapeutics initiated with a Buy at Lake Street
PremiumThe Fly
Bolt Biotherapeutics initiated with a Buy at Lake Street
18d ago
BOLT
GMAB
Genmab’s Strategic Forecast and Pipeline Potential Drive Buy Rating
PremiumRatings
Genmab’s Strategic Forecast and Pipeline Potential Drive Buy Rating
18d ago
GMAB
Genmab Executes Share Buy-back Transactions in May 2025
PremiumCompany Announcements
Genmab Executes Share Buy-back Transactions in May 2025
19d ago
6K
GMAB
Genmab price target lowered to $35 from $37 at H.C. Wainwright
PremiumThe FlyGenmab price target lowered to $35 from $37 at H.C. Wainwright
24d ago
GMAB
Genmab Executes Share Buy-back Transactions in May 2025
Premium
Company Announcements
Genmab Executes Share Buy-back Transactions in May 2025
26d ago
6K
GMAB
Genmab’s Strong Financial Performance and Promising Pipeline Justify Buy Rating
Premium
Ratings
Genmab’s Strong Financial Performance and Promising Pipeline Justify Buy Rating
26d ago
GMAB
Genmab’s Strong Performance Overshadowed by Patent Expiration Concerns and Competitive Challenges
PremiumRatings
Genmab’s Strong Performance Overshadowed by Patent Expiration Concerns and Competitive Challenges
29d ago
GMAB
Genmab upgraded to Buy from Hold at Nordea
PremiumThe Fly
Genmab upgraded to Buy from Hold at Nordea
29d ago
GMAB
Genmab Reports Strong Q1 2025 Earnings Growth
PremiumCompany Announcements
Genmab Reports Strong Q1 2025 Earnings Growth
29d ago
GMAB
Genmab Reports Strong Q1 2025 Financial Results and Product Approvals
PremiumCompany Announcements
Genmab Reports Strong Q1 2025 Financial Results and Product Approvals
30d ago
6K
GMAB
Genmab reports Q1 revenue $715M vs. $603M last year
PremiumThe FlyGenmab reports Q1 revenue $715M vs. $603M last year
30d ago
GMAB
Genmab reaffirms FY25 guidance
Premium
The Fly
Genmab reaffirms FY25 guidance
30d ago
GMAB
Genmab Executes Share Buy-back Transactions in Early May 2025
Premium
Company Announcements
Genmab Executes Share Buy-back Transactions in Early May 2025
1M ago
6K
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >